147595-55-9

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 598-21-0 2-Bromoacetyl bromide 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 497-25-6 dimethylenecyclourethane 

Downstream Products

• 142722-85-8 (4R,5S)-3-((2S,3R)-2-Bromo-3-hydroxy-pent-4-enoyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 345653-67-0 3-(11'(S)-(tert-Butyldiphenylsilyloxy)-3'S-hydroxy-6'E-dodecenoyl)-4R-methyl-5S-phenyl-2-oxazolidinone 
• 345653-68-1 3-(11'(S)-(tert-Butyldiphenylsilyloxy)-3'R-hydroxy-6'E-dodecenoyl)-4R-methyl-5S-phenyl-2-oxazolidinone 
• 288385-05-7 [4R-[3(R*),4α,5α]]-3-[4,4-dimethyl-1,5-dioxo-3-hydroxyheptyl]-4-methyl-5-phenyl-oxazolidin-2-one 
• 147725-28-8 (4R,5S)-3-<1-oxo-3-(1,3-dithian-2-ylidene)-2-<3,4-(methylenedioxy)benzyl>propyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 147725-24-4 (4R,5S)-3-<1-oxo-3-(1,3-dithian-2-ylidene)-2-benzylpropyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 147725-32-4 (4R,5S)-3-<1-oxo-3-(1,3-dithian-2-ylidene)-2-(2-propyl)propyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 147725-30-2 (4R,5S)-3-<1-oxo-3-(1,3-dithian-2-ylidene)-2-propylpropyl>-4-methyl-5-phenyl-2-oxazolidinone 
• 177977-02-5 C₃₆H₄₅NO₅S₂ 
• 177976-99-7 (4R,5S)-3-((E)-5-{2-[(2E,4E)-9-(4-Methoxy-benzyloxy)-nona-2,4-dienyl]-[1,3]dithian-2-yl}-pent-2-enoyl)-4-methyl-5-phenyl-oxazolidin-2-one 
• 177977-03-6 (4R,5S)-3-{(1R,2R,4aS,8aR)-2-[4-(4-Methoxy-benzyloxy)-butyl]-6-oxo-1,2,4a,5,6,7,8,8a-octahydro-naphthalene-1-carbonyl}-4-methyl-5-phenyl-oxazolidin-2-one 
• 227602-22-4 (4R,5S)-N-<5,5-(trimethylenedithio)-2(E),7(E),9-decatrienoyl>-4-methyl-5-phenyloxazolidin-2-one 
• 77943-39-6 4-methyl-5-phenyloxazolidin-2-one 
• 147725-15-3 diethyl 2-<(4R,5S)-4-methyl-2-oxo-5-phenyl-3-oxazolidinyl>-2-oxoethanephosphonate 

Relevant academic research and scientific papers

DERMAL COMPOSITIONS CONTAINING UNNATURAL HYGROSCOPIC AMINO ACIDS

Unnatural, hygroscopic amino acids are useful to enhance the moisture retention and uptake properties of skin. In particular, such amino acids are N-hydroxyserine, N- hydroxyglycine, L-homoserine,alpha-hydroxyglycine, 2-(aminooxy) -2-hydroxyacetic acid, 2-hydroxy-2-(hydroxyamino) acetic acid, 2- (aininooxy)acetic acid, and combinations thereof.

Epothilon derivatives, method for the production and the use thereof as pharmaceuticals

Disclosed are epothilone compounds of formula I, which are useful as pharmaceutical compounds for treating, for example, malignant tumors and chronic inflammatory diseases and are useful in anti-angiogenesis therapy.

EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE

This invention relates to the new epothilone derivatives of general formula I, 1in which substituents Y, Z R2a, R2b, R3, R4a, R4b, D—E, R5, R6, R7, R8 and X have the meanings that are indicated in more detail in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials. The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.

Synthesis of (7S,15S)- and (7R,15S)-dolatrienoic acid

The stereospecific synthesis of (7S,15S)- and (7R,15S)-dolatrienoic acids (2) was achieved using an approach consisting of 16 linear steps. The C-11-C-16 unit was prepared in seven steps from ethyl (S)lactate and coupled using a trans-selective Wittig - Schlosser reaction to the C-7-C-10 fragment. Chirality at the C-7 position was introduced using an Evan's-type chiral auxiliary in a cobalt-mediated Reformatsky reaction to give the (3S,11S)-aldehyde 24. Subsequent Wittig reaction with a phosphonium salt derived in three steps from tiglic acid gave (7S,15S)-dolatrienoic acid, one of the four possible diastereoisomers of the nonpeptide portion of the strong Cancer cell growth inhibitory cyclodepsipeptide dolastatin 14 (1). A second diastereoisomer, (7R,15S)-dolatrienoic acid, was synthesized employing chiral oxazolidinone 21 by an analogous synthetic route.

Studies on a total synthesis of plakotenin: Synthesis of optically active trans-hydrindanes by diastereoselective asymmetric intramolecular diels-alder reaction

Diastereoselective asymmetric intramolecular Diels-Alder reaction of 5,5-(trimethylenedithio)-2(E),7(E),9-decatrienoyl amides (13a-e) having various chiral auxiliaries was performed to give optically active trans- hydrindanes, which would be an important

Untersuchungen zur asymmetrischen Synthese von Stemona-Alkaloiden: Totalsynthese von (-)-Stenin

Keywords: Alkaloide; Asymmetrische Synthesen; (-)-Stenin; Totalsynthesen